Mustang Bio News | Markets Insider

TipRanks 90d

H.C. Wainwright Sticks to Its Buy Rating for Mustang Bio (MBIO)

TipRanks 95d

B.Riley Financial Sticks to Its Buy Rating for Mustang Bio (MBIO)

TipRanks 124d

BTIG Sticks to Its Buy Rating for Mustang Bio (MBIO)

Seeking Alpha 125d

Mustang Bio GAAP EPS of -$0.18 beats by $0.02

GlobeNewswire 125d

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire 144d

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's...

GlobeNewswire 165d

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma...

GlobeNewswire 193d

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

Zacks 198d

Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing

GlobeNewswire 220d

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Seeking Alpha 220d

Mustang Bio GAAP EPS of -$0.19 beats by $0.02

Benzinga 235d

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

GlobeNewswire 236d

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

Benzinga 236d

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday

MarketWatch 249d

Mustang Bio stock price target cut to $4 from $5 at B. Riley

GlobeNewswire 271d

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

Seeking Alpha 271d

Mustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug status

Seeking Alpha 279d

Mustang Bio updates interim data for blood cancer candidate

GlobeNewswire 280d

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Seeking Alpha 304d

Mustang announces positive data from gene therapy trial to treat X-linked immunodeficiency

GlobeNewswire 305d

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Benzinga 305d

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate

Seeking Alpha 310d

Catalyst watch: Twitter drama, high-profile Block and Caterpillar events, Jerome Powell talks

GlobeNewswire 311d

Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Seeking Alpha 311d

Mustang Bio GAAP EPS of -$0.20

GlobeNewswire 311d

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology...

GlobeNewswire 321d

Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell...

GlobeNewswire 329d

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

GlobeNewswire 333d

Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

GlobeNewswire 340d

Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma

Seeking Alpha 341d

Mustang Bio plans to start phase 1 trial of combo therapy for brain cancer

GlobeNewswire 350d

Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Benzinga 360d

63 Biggest Movers From Yesterday

Seeking Alpha 360d

Mustang Bio surges as Cantor views 2022 “as a year for execution”

Seeking Alpha 361d

Mustang Bio GAAP EPS of -$0.76 misses by $0.03

GlobeNewswire 361d

Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

GlobeNewswire 375d

Mustang Bio to Participate in Three March 2022 Investor Conferences

GlobeNewswire 376d

Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for...

GlobeNewswire 377d

Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital

GlobeNewswire 398d

Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

GlobeNewswire 405d

Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards

Seeking Alpha 418d

Mustang Bio down 9% following IND application hold, continuing rough year

Benzinga 419d

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

GlobeNewswire 419d

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients

Seeking Alpha 422d

Catalyst watch for next week: Earnings blitz headlined by Apple, Microsoft, Boeing and Tesla

GlobeNewswire 436d

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

GlobeNewswire 439d

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

Seeking Alpha 458d

Mustang Bio added to Nasdaq Biotech index

GlobeNewswire 459d

Mustang Bio Added to the NASDAQ Biotechnology Index

GlobeNewswire 462d

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

News for Mustang Bio Inc Registered Shs

Find News News